[This review was originally posted at the Nieman Journalism Lab Zoloft For Sale, on May 11, 2012.]
Slideshows, Facebook apps, and annoyed readers: After a few weeks revolving around News Corp., the media-watching world seemed to fixate on The Washington Post this week, focusing specifically on two developments: First, Adweek’s Lucia Moses reported that several top Post editors and reporters met with the newspaper’s president, Steve Hills, and that among other things, he urged them to produce more pageview-grabbing slideshows.
The Atlantic Wire’s Alexander Abad-Santos called it “one of the more disturbing things you’ll hear from someone in charge of one America’s best papers,” and his colleague, Alexis Madrigal, further explained the futility of slideshows. Those slideshows, he argued, Zoloft pics, may be producing more pageviews, but they’re not actually drawing more people. And the people that do read them come away with the feeling that the site doesn’t value them. “People know when your product is cheap; there is no ‘trick’ of the web,” he wrote.
The second development came when Forbes’ Jeff Bercovici reported that the number of users of its Facebook Social Reader had dropped precipitously over the past month or so, Zoloft For Sale. Zoloft photos, BuzzFeed’s John Herrman noticed that a lot of other Facebook social apps have experienced a similar drop, including The Guardian’s, and proposed that the decline might be because the apps just enable too much sharing, even for Facebook: “they felt more like the kind of cold, descriptive, invisible and yet mandatory services we’re used to seeing from Google rather than genuinely new and useful tools for spreading information.” SF Weekly’s Dan Mitchell agreed, calling the apps “spam, purchase Zoloft for sale, basically.”
But there seemed to be something amiss with such a simple explanation. Jeff Sonderman of Poynter noticed that there was a huge change in most apps’ statistics around April 10, and TechCrunch’s Josh Constine hypothesized that the drop was a result of Facebook’s transition to “Trending Articles,” which made social reader articles much less prominent in users’ news feeds. That theory was confirmed by editors at the Post and the Guardian, Fast shipping Zoloft, as the Lab’s Justin Ellis found.
From this explanation came a different lesson for news orgs — as GigaOM’s Mathew Ingram argued, with a social reader, “Facebook owns you, in the sense that it controls access to your content. Zoloft For Sale, It controls who sees it and when, and it controls how it is displayed — or even whether it is displayed.” Sonderman made a similar point and also touched on the user annoyance issue.
Facebook, for its part, australia, uk, us, usa, countered that engagement on many of its social apps is up, and Poynter’s Andrew Beaujon pointed out that even though there was a valid logistical explanation for the user decline, many observers still insisted on sticking to user annoyance as the root cause.
As Huffington told it, she asked for the role reduction as an attempt to focus more specifically on HuffPo and gain more independence for her site, herbal Zoloft. She also said she’d been approached by private-equity firms trying to buy HuffPo from AOL, though she said nothing had come of it. Huffington insisted her relationship with AOL CEO Tim Armstrong was fine, but others were skeptical, Zoloft For Sale. New York magazine’s Joe Coscarelli said it’s tough not to see this as “a crack in the facade of a relationship many believed to be doomed from the start.”
GigaOM’s Mathew Ingram was similarly dubious, and he also explored some possibilities for a HuffPo sale, concluding that Huffington will either take her site private again or end up taking over the whole operation at AOL. Where can i cheapest Zoloft online, Forbes’ Jeff Bercovici wondered why AOL doesn’t just sell HuffPo anyway, but reasoned, as Ingram did, that AOL has invested all of its content resources into HuffPo, leaving the company with very little in the way of media if it were to sell. AOL, he argued, overpaid for HuffPo on the premise that it could replicate the site’s model across its other properties, real brand Zoloft online, which hasn’t panned out.
AOL also announced its most recent quarterly earnings, which were higher than expected, though one of its key ad metrics was down, and, Is Zoloft safe, as All Things D’s Peter Kafka reported, its traffic continues to slide. Meanwhile, PandoDaily (made up largely of ex-TechCrunchers) reported that AOL is shopping TechCrunch and Engadget for $70 million to $100 million. Armstrong denied Zoloft For Sale, that, and TechCrunch said the rumors of a sale actually originated from AOL’s aborted plans to spin the two blogs into their own company.
Amid all this, News Corp.’s profits keep growing. Its net income grew 47 percent, and its profits, announced this week, Zoloft no prescription, beat analysts’ estimates. The company’s costs from the scandal keep soaring, too, hitting $167 million since last summer. The New York Times’ David Carr said News Corp.’s continued profits and its board’s ongoing support of Rupert Murdoch might make him still seem invincible, Buy Zoloft from canada, but he’s still on an irreversible fall. Zoloft For Sale, He pinned much of blame for News Corp.’s tone-deafness on the board, saying that “the primary reason Mr. Murdoch has not been held to account is that the board of News Corporation has no independence, little influence and no stomach for confronting its chairman.” Former Times editor Bill Keller, meanwhile, said Murdoch’s greater shame will be Fox News’ pretensions at honest journalism.
Reading roundup: A few smaller stories running a little bit more under the radar this week:
— Jason Pontin of Technology Review wrote a piece on how publishers have grown disillusioned with apps after expecting them to do so much to restore their old business models, concluding regarding his own publication’s app experience: “I hated every moment of our experiment with apps, where can i order Zoloft without prescription, because it tried to impose something closed, old, and printlike on something open, new, and digital.” GigaOM’s Mathew Ingram echoed Pontin’s discontent with apps, and Dave Winer and Doc Searls touted the superiority of rivers of news over apps.
— The New York Times’ Binyamin Applebaum documented the frenetic daily routine of Business Insider blogger Joe Weisenthal, and Reuters’ Felix Salmon responded that Weisenthal’s style isn’t something indicative of bloggers in general, but unique to his distinctive personality.
— Finally, Belgian developer Stijn Debrouwere wrote a fantastic post on the astounding number of ways that journalism is being chipped away at by services and sites that aren’t journalistic themselves, but that are being consumed by people instead of news. Give it a read — it’s probably the best piece about the state of journalism yet this year.
Similar posts: Zoloft No Rx. Bactrim For Sale. Glucophage Price. Tramadol coupon. Glucophage for sale. Cephalexin reviews.
Trackbacks from: Zoloft For Sale. Zoloft For Sale. Zoloft For Sale. Where can i find Zoloft online. Where can i order Zoloft without prescription. Order Zoloft online c.o.d.
[This review was originally posted at the Nieman Journalism Lab Cephalexin Over The Counter, on April 20, 2012.]
The Pulitzers and HuffPo’s arrival: The Pulitzer Prizes were awarded this week, accompanied as usual by tears and impromptu speeches in newsrooms around the country (documented well by Jeff Sonderman on Storify). On the meta-level, the Washington Post’s Erik Wemple criticized the awards’ secrecy, but Dean Starkman of the Columbia Journalism Review offered a defense of having such publicly celebrated industry awards in the first place, arguing that during an era when news organizations have become so adept at measuring journalism quantity, the Pulitzers are one of the few barometers left for journalism quality, get Cephalexin.
As for this year’s awards themselves, the American Journalism Review’s Rem Rieder pointed out that while the Pulitzers are usually dominated by a few heavy hitters, this year brought several feel-good stories. One of those was the Pulitzer won by the Philadelphia Inquirer, Buy cheap Cephalexin no rx, the once-great paper that has had an extremely rough last several years and was sold yet again for a bargain-basement price just a few weeks ago. Poynter’s Steve Myers reported on the award’s impact, which one reporter called “a wonderful burst of hope.”
Another remarkable Pulitzer winner was Sara Ganim of the Patriot News of Harrisburg, Pennsylvania, who at 24 became one of the youngest Pulitzer winners ever for her reporting on the Penn State sex abuse scandal. Poynter’s Mallary Tenore explained how she took the lead on the story at two different papers, Cephalexin Over The Counter. Not all the news was heartwarming, Cephalexin canada, mexico, india, though — there was no prize for editorial writing. Erik Wemple explained why (nothing personal!), but Gawker’s Hamilton Nolan loved the decision, calling editorials “a worthless anachronism in this modern media age.”
But the biggest theme in this year’s Pulitzers was the prominence of online journalism: The online-only Huffington Post and the very online-centric Politico both won prizes, Cephalexin online cod, which the Lab’s Adrienne LaFrance called a victory for their fast-paced, aggressive editorial models. Additionally, Twitter played a big role in the tornado coverage that earned Alabama’s Tuscaloosa News a Pulitzer, as Poynter’s Jeff Sonderman detailed.
Of those online-oriented Pulitzers, order Cephalexin online c.o.d, the Huffington Post’s drew the bulk of the attention. HuffPo’s Michael Calderone and Poynter’s Mallary Tenore Cephalexin Over The Counter, both told the story behind HuffPo’s award-winning story, and in an AP story, Ken Doctor called it an arrival of sorts for HuffPo, while VentureBeat’s Jolie O’Dell called it a win for quality blogs everywhere. PaidContent’s Staci Kramer said HuffPo’s win shows the old guard has finally learned that the work, not the medium, is the message. Order Cephalexin from mexican pharmacy, Both GigaOM’s Mathew Ingram and NYU prof Jay Rosen (in Calderone’s article) pointed out that this isn’t as much of a “new media vs. old media” win as people might think; traditional news orgs and digital outfits have been looking more and more alike for quite some time now.
There was also quite a bit of other talk about HuffPo’s model this week, though most of it wasn’t directly related to the Pulitzers. Media blogger Andrew Nusca expressed his frustration with the parade of “awful posts and shameless slideshows” that populates most of HuffPo and its competitors, and the Columbia Journalism Review published an in-depth story on how HuffPo developed its distinctive model and why it works. Meanwhile, the Lab’s Justin Ellis wrote on HuffPo’s refusal to employ false balance when covering climate change and Folio reported on its coming magazine iPad app, Cephalexin Over The Counter.
Amazon under fire: A week after the U.S, purchase Cephalexin. Justice Department sued Apple and five major book publishers for antitrust violations (paidContent’s Laura Hazard Owen has a good description of what it means for readers), most of the attention shifted to the biggest ebook player not involved in the lawsuit: Amazon. The New York Times reported on a small publisher that has removed its titles from Amazon out of frustration that the retailer’s low prices were undercutting its own booksellers.
CNET’s Greg Sandoval talked to other small publishers who see Amazon as a much bigger threat than Apple, Get Cephalexin, and at the Daily, Timothy Lee urged the U.S. government Cephalexin Over The Counter, to change copyright law to allow Amazon’s competitors to convert Kindle books to be compatible with other devices. The New York Times’ David Carr gave the most ominous warning of Amazon’s below-cost ebook pricing’s effect on the publishing industry, saying that with the suit, “Now Amazon has the Justice Department as an ally to rebuild its monopoly and wipe out other players.”
Novelist Charlie Stross went into the economics of Amazon’s ebook strategy, comparing it to big-box retailers that wipe out mom-and-pop stores with their extremely low pricing: “Amazon has the potential to be like that predatory big box retailer on a global scale, Cephalexin overnight. And it’s well on the way to doing so in the ebook sector.” Forbes’ Tim Worstall pushed back against Stross’ characterization, arguing that Amazon doesn’t have a monopoly on the ebook market because it’s still extremely easy to put ebooks on a server, achieve some scale and contest Amazon’s dominance.
Amazon’s Jeff Bezos, Cephalexin from mexico, for his part, released a letter to shareholders last Friday that asserted that “even well-meaning gatekeepers slow innovation.” Techcrunch’s John Biggs said this philosophy makes sense in the world of networked information, but Wired’s Tim Carmody said Amazon is really trying to draw a contrast between its own infrastructure-based model and the product-based “gatekeeping” model of its chief competitor, Apple.
Elsewhere, Ross Douthat of the New York Times used Google’s recently unveiled Project Glass, Herbal Cephalexin, which would bring all the information of a smartphone in front of our eyes in the form of glasses, as a warning against the possibility of a sort of hyper-surveillance techno-tyranny. Web philosopher Stowe Boyd ripped Douthat’s assertion that Google’s glasses are a reflection of our growing loneliness. (Slate’s Eric Klinenberg wrote a more thorough takedown of the “we’re getting lonelier” hypothesis, targeting Atlantic’s recent article on Facebook.) And late last week, Google’s news products chief, Cephalexin pharmacy, Richard Gingras wrote at the Lab about the questions that will define the future of journalism.
— Facebook has begun testing “trending articles” as a way to get more people to use its social news apps, though ReadWriteWeb’s Jon Mitchell said those apps, No prescription Cephalexin online, and the “frictionless sharing” they depend on, aren’t working. Cephalexin Over The Counter, Meanwhile, the Atlantic’s Alexis Madrigal said it’s time to get past the Facebook mentality of social networking and figure out what’s next for the Internet.
— NYU prof Jay Rosen wrote about a fascinating question that’s been puzzling him for years — Why does the American public trust the press so much less than it used to? — positing a few possible explanations and asking for more ideas. You can also hear Rosen talking about the state of the media and the public in this Radio Open Source podcast.
— Two more intriguing entries on the ongoing series of posts on how people get their news, these from News.me: Digital media researcher danah boyd, buy cheap Cephalexin no rx, who talked about young people’s news consumption, and former New York Times digital chief Martin Nisenholtz, who talked about the Times’ transition into a digital world.
— Finally, the Times’ Brian Stelter wrote a thoughtful piece on the fleeting nature of today’s information environment, and the ephemeral, hyperactive common conversation it gives us.
Similar posts: Bactrim Cost. Tramadol For Sale. Order Retin A. Buy Lipitor without prescription. Bactrim interactions. Effects of Lipitor.
Trackbacks from: Cephalexin Over The Counter. Cephalexin Over The Counter. Cephalexin Over The Counter. Buy cheap Cephalexin. Cephalexin price. What is Cephalexin.
[This review was originally posted at the Nieman Journalism Lab Buy Retin A No Prescription, on Aug. 12, 2011.]
Murdoch passes Wall Street's test: The fallout from News Corp.'s phone hacking scandal continued to spread this week, with the reported arrest of another former News of the World editor and the report that the ostensibly fired News Corp. British chief, Rebekah Brooks, Retin A alternatives, is still on the company payroll.
Three weeks after testifying before Parliament, Rupert Murdoch faced Wall Street analysts this week in a conference call, telling them that he's not going anywhere and that the scandal hasn't done any material damage to the company outside of News of the World. Purchase Retin A, All Things Digital's Peter Kafka said Wall Street really doesn't care about the hacking, and Murdoch didn't say much about the few questions he did get on it.
Murdoch also had to meet with News Corp.'s board, but as the New York Times' Jeremy Peters reported, the board's officially independent members include numerous people who have deep personal ties to Murdoch, Buy Retin A No Prescription. Perhaps more troubling was a different connection among one of the board members: According to Time's Massimo Calabresi, one of them is "best friends" with the district attorney leading the U.S. investigation into the company.
The Times' David Carr uncovered more hints at News Corp.'s enormous political influence here in the States, Retin A pics, detailing cases of swift approval of a merger by a Justice Department unit led by a future News Corp. executive, as well as a suspiciously dropped federal criminal case. "The company’s size and might give it a soft, less obvious power that it has been able to project to remarkable effect, Buy Retin A without prescription, " Carr concluded. Buy Retin A No Prescription, At Adweek, Murdoch biographer Michael Wolff went further, reporting that the Justice Department is considering investigating News Corp. on racketeering charges, though Forbes' Jeff Bercovici doubted that would happen. For a bit more info on the situation, here's a good Q&A with Nick Davies, the Guardian reporter who's been all over the story, order Retin A no prescription.
AOL's slap from investors: This week hasn't been a good one for AOL: After it reported a quarterly loss on Tuesday, its stock dropped by about a quarter by the end of the day. All Things Digital's Peter Kafka gave a quick explainer of why investors are so down on AOL: What little money they're making isn't coming from the all-important display advertising business. Mathew Ingram of GigaOM added more depth to that analysis, arguing that investors are doubting AOL's assurances that its two big gambles — Patch and the acquisition of the Huffington Post — will pay off, Buy Retin A No Prescription.
According to AOL CEO Tim Armstrong (paraphrased by Business Insider), Retin A price, coupon, the reason for those problems is that AOL's advertising side hasn't scaled well enough. Peter Kafka explained that AOL's advertising (especially display) is indeed up, though much of that can be attributed to the HuffPo and TechCrunch acquisitions. Forbes' Jeff Bercovici said AOL's public image problem has even damaged the previously successful HuffPo, quoting an analyst who called AOL a "dead brand." Wired's Tim Carmody decided to unite our two big stories this week and suggested that AOL would be a perfect fit for a purchase by News Corp.
Meanwhile's AOL's local-news initiative, Retin A samples, Patch, launched a Groupon-esque daily deal service, and Iowa grad student Robert Gutsche Jr.questioned Patch's standards for separating journalism and advertising — and got the runaround from Patch when he asked them about it. AOL's new daily tablet magazine, Editions, Buying Retin A online over the counter, also drew some criticism, with Fast Company's Austin Carr perturbed that it's not AOL-y enough.
A news org gets into tablets Buy Retin A No Prescription, : We've already seen numerous challengers to the iPad's early stranglehold on the tablet marketplace, but the Tribune Co. might be the first news company to try one out. CNN's Mark Milian reported that the newspaper chain is working on an Android-based tablet, which it's planning on offering it for free or very cheap to people who sign up for extended newspaper subscriptions. It's already missed a mid-August deadline for testing the tablet out, purchase Retin A online.
Media pundits didn't think much of the Tribune's idea. Wired's Tim Carmody urged the Tribune (and media companies in general) to quit developing tablets, arguing that it's way too hard to do if you're a major development company, let alone a news organization. "If major publishers are seriously prepared to blow up their primary revenue stream — print advertising — and slap together a giveaway tablet in order to save money on ink, God help them," he wrote, Buy Retin A No Prescription.
Others echoed Carmody's arguments: PaidContent's Tom Crazit called the project "a colossal waste of money for a company trying to emerge from bankruptcy." Chris Velazco of TechCrunch said the cheap-tablet model (also being talked about by Philadelphia Newspapers) isn't viable. Gizmodo's Brent Rose was less restrained: "WHY??" Morris Communications' Steve Yelvington was a little kinder to the Tribune, saying the numbers might add up, Kjøpe Retin A på nett, köpa Retin A online, but the devil's in the details.
The Times gets experimental: The New York Times has frequently made strong pushes into news innovation over the past several years, and this week it started another one, launching a new public test kitchen for projects in development. The Lab's Megan Garber explained what the site, beta620, Retin A for sale, is all about, but GigaOM's Mathew Ingram, while applauding the effort, expressed some doubt about whether the Times is really capable of developing a startup's mindset. Buy Retin A No Prescription, Tim Carmody of Wired, on the other hand, said the startup analogy isn't the right one for the Times. Retin A online cod, With these projects, he said, "The New York Times has become an openly experimental public institution. It’s less a cathedral consecrated to its own past than a free museum where patrons are invited to touch and transform everything they see." Poynter's Jeff Sonderman had some suggestions for next steps for the Times to take with beta620: experimenting with design, getting away from the long narrative article, and rethinking comments, Retin A trusted pharmacy reviews.
The real-name debate: One long-simmering debate I want to briefly catch you up on: Google+ has decided to take the Facebook route of disallowing pseudonyms, adjusting but reaffirming its policy in the face of online criticism late last month and again on Thursday. The outcry continued, voiced most prominently late last week by social media researcher danah boyd, Order Retin A from mexican pharmacy, who asserted that "'real names' policies aren’t empowering; they’re an authoritarian assertion of power over vulnerable people."
Liz Gannes of All Things Digital said she understands Google's motivations for enforcing real names and unifying everything under its umbrella within the same identity, but the idea of doing the latter is awkward at best and frightening at worst. The Atlantic's Alexis Madrigal, meanwhile, announced he's changed his mind against real-name policies, arguing that requiring real names online is a radical departure from the relationship between speech and identity in the offline world, Buy Retin A No Prescription.
Reading roundup: A few other things to keep an eye on this week:
— Amazon released a version of its Kindle app for browsers, called the Kindle Cloud Reader. GigaOM's Mathew Ingram said the browser-based e-book app (which bypasses Apple's restrictions) could be a roadmap for the future of the web, but Wired's Tim Carmody said it still doesn't get the web, Retin A without prescription.
— Google announced it's making its hand-chosen Editors' Picks a standing feature on Google News. The Lab's Megan Garber explained what Google's doing with it. Buy Retin A No Prescription, Meanwhile, James Gleick at The New York Review of Books offered a thoughtful piece on Google's domination of our online lives.
— Adweek explained an underrated obstacle to innovation and progress in news organizations' online efforts: the intractable CMS.
— Steve Buttry, now with the Journal Register Co., gave his lessons from TBD's demise on the Washington local news site's first birthday. It's short but solid. Enjoy.
Similar posts: Purchase Retin A. Order Cephalexin. Buy Zoloft No Prescription. Armour for sale. Where can i buy Cephalexin online. Synthroid without prescription.
Trackbacks from: Buy Retin A No Prescription. Buy Retin A No Prescription. Buy Retin A No Prescription. Retin A duration. Retin A images. Retin A australia, uk, us, usa.
[This review was originally posted at the Nieman Journalism Lab Purchase Glucophage, on July 18, 2011.]
News Corp.'s scandal keeps growing: Rupert Murdoch might have hoped News Corp.'s phone hacking scandal would die down when he closed the British tabloid News of the World last week, but it only served to fuel the issue's explosion. This past week, the scandal's collateral damage spread to News Corp.'s proposed takeover of the British broadcaster BSkyB: Faced with increasing pressure from the British government and the revelation that News Corp. journalists tried to get private records of former Prime Minister Gordon Brown, News Corp. dropped the BSkyB bid, which had been a huge part of the company's U.K. strategy. Buy no prescription Glucophage online, Plenty of other problems are cropping up for News Corp., too. The top lawyer for its U.K, Purchase Glucophage. newspaper branch, News International, quit. The company's stock lost $7 billion in four business days at one point. A pre-existing U.S. shareholders' suit expanded to cover the hacking scandal, is Glucophage addictive. The Murdochs have to testify before British Parliament Purchase Glucophage, this week about the scandal, and the FBI started investigating U.S.-related aspects of the issue. That's all in addition to the ongoing problems News Corp. faces, as detailed by Poynter's Rick Edmonds.
The scandal has led quite a few writers to criticize the culture that Murdoch has created at News Corp. Capital New York's Tom McGeveran and Reuters' John Lloyd railed on Murdoch and News Corp.'s character, Carl Bernstein called this Murdoch's Watergate, Canada, mexico, india, and the Observer's editorial board called for systemic reforms in Britain so Murdoch's influence can never be so strong. Members of the Bancroft family said they wouldn't have sold the Wall Street Journal to Murdoch in 2007 if they'd have known the hacking was going on, Purchase Glucophage.
On the other hand, the New York Times pointed out that sleazy British tabloid tactics are hardly limited to Murdoch, and media critic Howard Kurtz noted that they're very much alive in the U.S. mainstream press, too. New York Times columnist Roger Cohen defended Murdoch, saying he's been good for journalism on the whole, purchase Glucophage online, and Gawker's John Cook defended those tabloid reporting tactics. Meanwhile, j-prof Jeff Jarvis and the Telegraph's Toby Harnden urged the British government not to respond by enacting more regulation. Purchase Glucophage, News Corp.'s retreat might not stop with News of the World and BSkyB. Murdoch biographer Michael Wolff and others have reported that the company's execs are debating whether to get out of Britain's newspaper business entirely, and several observers chimed in to say that might actually make a good deal of business sense. Media analyst Ken Doctor said News International is losing steam, After Glucophage, and the Financial Times' John Gapper said newspapers are becoming far more trouble than they're worth to Murdoch.
Not only that, but the New Yorker's John Cassidy said dropping his U.K. newspapers could let Murdoch revive his BSkyB bid, and Jeff Jarvis speculated that when Murdoch chooses between the power that the papers give him and the money saved by getting rid of them, he'll choose the money. In an interview with the Wall Street Journal, Murdoch called the rumors of a newspaper sell-off "rubbish."
But just because News of the World and News International may be dead and dying, that doesn't mean newspapers as a whole are, argued David Carr of the New York Times, Purchase Glucophage. As he noted, it was the Guardian's dogged reporting that finally broke this story open. Murdoch "prefers his crusades to be built on chronic ridicule and bombast, Glucophage used for. But as The Guardian has shown, the steady accretion of fact — an exercise Mr. Murdoch has historically regarded as bland and elitist — can have a profound effect," Carr wrote. The Atlantic also had praise for the Guardian, and Poynter's Mallary Jean Tenore interviewed one of its editors about the lonely journey of covering the phone hacking story.
HuffPo aggregation under the microscope Purchase Glucophage, : A lively discussion about the rights and wrongs of aggregation developed last week out of a column by Ad Age media critic Simon Dumenco, who complained that the Huffington Post had extensively summarized one of his posts, buried the link to the original, and — contrary to Arianna Huffington's argument that her site benefits those they aggregate by sending them readers — gave him just 57 page views. Buy Glucophage without a prescription, The Huffington Post responded by apologizing and suspending the article's writer. HuffPo business editor Peter Goodman told Adweek the piece was a fully formed article when it should have been a simple introduction and a link, but Dumenco responded to the apology by arguing that the writer did nothing out of the ordinary — this is just how HuffPo tells its writers to do it.
Dumenco's point was echoed by several others: The Awl's Choire Sicha said the suspended writer was doing what she was taught, Gawker's Ryan Tate, drawing on a revealing quote from a former HuffPo writer, made the same point: "This is pretty ridiculous, given HuffPo's systematic, Glucophage dosage, officially-sanctioned approach to rewriting too much of people's news articles." British journalist Kevin Anderson called HuffPo's summary-heavy aggregation "a pretty cynical strategy," and paidContent's Staci Kramer said HuffPo needs to respect its sources, rather than treating a link as a favor.
Gabe Rivera, whose news site, Techmeme, Where can i order Glucophage without prescription, was compared to HuffPo favorably by Dumenco, looked for terms to distinguish what his site does from what HuffPo does. Poynter's Julie Moos said some measure of originality will always make for better journalism and a better business model than heavy aggregation, and ZDNet's Tom Foremski pined for the old blogging mentality whose goal was to add value, Purchase Glucophage. In a short podcast, author Steven Rosenbaum said this is a logical time to step back and evaluate exactly what constitutes ethical aggregation.
There were a few dissenters, though: GigaOM's Mathew Ingram and Slate's Jack Shafer both argued that the type of aggregation that HuffPo does has been around for ages in traditional media (especially in Britain, according to Forbes' Tim Worstall). In fact, Glucophage coupon, Shafer said, news orgs could learn a something valuable from the Huffington Post: "That a huge, previously ignored readership out there wants its news hot, quick, and tight."
Comparing Google+, Facebook, Cheap Glucophage, and Twitter: It's been just about three weeks since Google+ launched, and Google's new social network is growing like a weed, with estimates of as many as 10 million users so far. (Its number of active users may soon be approaching Twitter's figures.) Google+ news has dominated Twitter, and Google's also working on integrating it with Gmail. Purchase Glucophage, With Plus' incredible growth, tech observers have been going back and forth about what social network Google+ is disrupting most. PCWorld's Megan Geuss wondered whether Google+ and Facebook can coexist, and PC Magazine's John Dvorak posited that all the excitement about Google+ is more or less just pent-up frustration with Facebook. The New York Times' David Pogue and Technology Review's Paul Boutin both compared Google+ favorably to Facebook, largely because of its superior privacy controls (though GigaOM's Mathew Ingram pointed out that it may not be a privacy improvement for some people).
Meanwhile, Search Engine Land's Danny Sullivan said Google+ is more comparable to Twitter, Glucophage natural, then went ahead and made a thorough, smart comparison between the two. The Atlantic's Alexis Madrigal said Google+ might end up being more conversational than Twitter, which he called more of a call-and-response: Google+ "won't be as good at connecting people to information or each other quickly, but it might be better at longer form discussions and whatever we call the process by which people pull reasoned thoughts from their networks into public discourse." Hutch Carpenter said Google+ resembles both Facebook and Twitter, and Computer World's Mike Elgan wrote that it'll disrupt just about everything.
Still, Google+ has its limits: ReadWriteWeb's Marshall Kirkpatrick explained why he'd never move his personal blog there as some are doing, and Instapaper's Marco Arment and the Guardian's Dan Gillmor both urged readers to keep a space for their own online identity outside of spaces like Google+ or Facebook, Purchase Glucophage. For journalists feeling out Google+, Meranda Watling of 10, Glucophage from canada,000 Words put together a preliminary guide.
Reading roundup: Here's what else people were talking about this past week:
— The newspaper chain MediaNews made a distinctive play for the tablet news market last week, announcing the launch of TapIn, a location-based news app made specifically for tablets. It'll start in the Bay Area in partnership with the San Jose Mercury News. Ken Doctor, Jeff Sonderman, Glucophage overnight, and Mathew Ingram all wrote about what makes it worth watching.
— The Economist continued running pieces all week in its series on the future of the news industry. You can check out several writers'reasons for optimism or read the opening statements in an ongoing debate between NYU's Jay Rosen and author Nicholas Carr about whether the Internet has been good for journalism.
— Boston Globe developer Andy Boyle made his pitch for young journalists to go into web development, or as he put it, "learn to make the internets."
— Poynter's Jeff Sonderman put together two great social media how-to's for journalists: One on verifying information on social media, and the other on strategies for engagement on Facebook.
— Finally, NYU's Clay Shirky gave us another thoughtful essay on the unbundling of news and why the news ecosystem needs to be chaotic right now. In the end, though, here's what he believes news should be: "News has to be subsidized because society’s truth-tellers can’t be supported by what their work would fetch on the open market"; "news has to be cheap because cheap is where the opportunity is right now"; and "news has to be free, because it has to spread.".
Similar posts: Zoloft No Rx. Bactrim For Sale. Glucophage Price. Tramadol coupon. Glucophage for sale. Cephalexin reviews.
Trackbacks from: Purchase Glucophage. Purchase Glucophage. Purchase Glucophage. Glucophage dose. Buying Glucophage online over the counter. Rx free Glucophage.
[This review was originally posted at the Nieman Journalism Lab Armour Dosage, on May 6, 2011.]
Twitter as breaking-news system: This week's big news is obvious: American forces killed Osama bin Laden on Monday (Sunday for most Westerners) in a raid of his compound in Abbottabad, Pakistan. But you already knew that, and how exactly you found out is the first angle I want to look at. The news blew up on Twitter and Facebook late Sunday night after the White House announced President Obama would be addressing the nation. The ensuing frenzy set a record for the highest volume of sustained activity on Twitter, with an average of 3, Armour results, 000 tweets per second for about three hours. While most Americans first got the news from TV, about a fifth of young people found out online.
That led to another round of celebration of Twitter as the emerging source for big breaking news — Business Insider's Matt Rosoff called the story Twitter's CNN moment and said Twitter was "faster, more accurate, and more entertaining than any other news source out there." PR guru Brian Solis described Twitter as "a perfect beast for committing acts of journalism," and University of British Columbia j-prof Alfred Hermida said it's becoming routine to see Twitter as the first option for breaking news coverage, Armour Dosage.
Others pushed back against that praise: Advertising Age's Simon Dumenco argued that everyone on Twitter was still waiting for confirmation from government officials and the mainstream media, and Dan Mitchell of SF Weekly said that most of the people tweeting the news were from traditional media anyway. The American Journalism Review's Rem Rieder said the aide who broke the story on Twitter wasn't doing journalism, but just passing on a rumor, Armour description. And Engadget vet Joshua Topolsky said the Twitter buzz probably says more about our need to tell others we got to the news first than it does about Twitter.
Several folks staked out a spot between the two positions. TechCrunch's Erick Schonfeld Armour Dosage, said Twitter doesn't supplant traditional media, but it does amplify it and drive people to it. GigaOM's Mathew Ingram advised us to think about it not in terms of competition between old and new media, but as part of a news ecosystem: "it’s not really about Twitter or Facebook; it’s about the power of the network." Elsewhere, media analyst Dan Gillmor compared this story to how the 9/11 news broke, Armour gel, ointment, cream, pill, spray, continuous-release, extended-release, GigaOM's Stacey Higginbotham classified the seven stages of breaking news on Twitter, and Search Engine Land's Danny Sullivan looked at the way Google responded to the story.
Three other mini-stories within the digital aspect of the Bin Laden story: First, regarding traditional media outlets' online efforts, former Guardian digital chief Emily Bell wrote a fantastic piece about how live news coverage is the great challenge of our time for news orgs, the Online Journalism Review's Robert Niles critiqued the performance of mobile news sites, and the BBC's Rory Cellan-Jones ripped some news iPad apps for being slow with the story, ordering Armour online.
Second, there was plenty of discussion about the remarkable story of Pakistani programmer Sohaib Athar, who live-tweeted the raid without knowing it. Poynter's Steve Myers went meta with the account of how we found out about him, revealing some interesting examples of how information travels through a network like Twitter. He then defended Athar as a citizen journalist, Armour Dosage. Armour dosage, And third, the Atlantic's Megan McArdle explained how a quotation got misattributed to Martin Luther King Jr. and then went viral, and Frederic Lardinois of NewsGrange mused about the difficulty of social media corrections.
Osama and the Times' pay wall: While we've been focusing on the digital media side of things so far, Bin Laden's death was the type of massive story that traditional news organizations go into overdrive on, too, buy no prescription Armour online. Poynter and the Columbia Journalism Review have great looks at how news orgs played the story in print and online, and we got some behind-the-scenes glimpses at how the New York Times, Chicago Tribune, What is Armour, CNN, and other mainstream journalists put together reports on such quick deadlines. Armour Dosage, The Times made an interesting decision in the wake of the story not to lift its pay wall/gate/fence for news on Bin Laden's death, even though it had previously expressed a willingness to allow free access for big stories. The Lab's Megan Garber asked a number of questions about that issue — who makes that decision. And if this isn't a huge story, what is? — and noted that the fact that it was the beginning of the month and many users' meters had just been reset played into the decision.
Meanwhile, James Rainey of the Los Angeles Times criticized the cheerleading tone of TV news' coverage, and Slate's Jack Shafer called out some of the inaccuracies in news stories on Bin Laden's death.
Giving reporters social-media leeway: We saw a case study in contrasting newsroom social media policies, starting when Bloomberg' guidelines were leaked to eMedia Vitals last week. It encouraged reporters to use Twitter, with several restrictions listed under one strong caveat: "Ask questions first, Armour Dosage. Armour maximum dosage, Tweet later."
A couple of days later, John Paton of the Journal Register Co. posted his own company's social media policy. It was blank — implying that the company doesn't put any explicit restrictions on what or how employees can post. Techdirt's Mike Masnick praised Paton's philosophy: "These things are developing quickly, and for people to find out how to use these tools most efficiently and effectively, they need to feel free to experiment and do whatever needs to be done."
That prompted GigaOM's Mathew Ingram to give his own social media advice for journalists, buy cheap Armour no rx, telling them to talk to people, link, retweet, reply when spoken to, admit when they're wrong and be human — but not too human. Armour Dosage, Michele McLellan of the Knight Digital Media Center, meanwhile, defined online engagement in terms of outreach, conversation, and collaboration. Armour trusted pharmacy reviews, —
Publishers begin to jump in with Apple: A couple of big media-on-iPad developments this week: Time Inc. reached a deal with Apple to allow magazine subscribers to get iPad apps for free, and Hearst became one of the first major publishers to agree to offer subscriptions within iPad (which means Apple's getting that 30% cut), though Advertising Age's Nat Ives wondered if Condé Nast will beat Hearst to the punch.
The British newspaper the Telegraph also launched an iPad edition, and the Guardian's Stuart Dredge noted that both the Telegraph and Hearst are asking customers to share their personal data with them (Apple already gets customer data), and the Telegraph is giving an incentive to them to do so. Meanwhile, Armour without a prescription, the company Yudu has launched some sort of service that will somehow allow publishers to evade Apple's 30% in-app subscription cut and apparently got Apple's approval. (As you can tell, details are sketchy at this point.)
Elsewhere in news on the iPad, News Corp. said it's lost $10 million on The Daily this quarter, which has reportedly gotten 800,000 downloads, Armour Dosage. Former Marketwatch CEO Larry Kramer said The Daily is gradually getting better, Purchase Armour, though.
Pardon AOL's dust: Arianna Huffington keeps on cleaning house at AOL, with a handful of new changes each week. This week: AOL News was folded into the Huffington Post, and Patch announced they're launching Patch Latino sites in California and unveiled the hyperlocal blogging network for which it's been recruiting volunteers for the past couple of weeks. Forbes' Jeff Bercovici reported that AOL is continuing to pour millions of dollars into Patch and expects to lose money on the site this year. Armour Dosage, Even if Patch works journalistically, Mathew Ingram said, that doesn't mean it'll make any business sense.
The Next Web's Alex Wilhelm warned of the homogenization threatened by the AOL content empire and NPR's On the Media debated whether the Huffington Post is good for journalism, japan, craiglist, ebay, overseas, paypal. Amid the hand-wringing, Lauren Rabaino of 10,000 pointed out five good things Patch sites are doing, including transparency and accountability by editors.
Reading roundup: Believe it or not, Armour pictures, people in media circles talked about things this week that didn't have to do with Osama bin Laden or AOL. Here are a few of them:
— Marco Arment's post last week about his successful experiments in charging for Instapaper turned into an interesting discussion about creating a freemium or "business class" for news. Here's Frederic Filloux, Oliver Reichenstein, and Mathew Ingram, Armour Dosage.
— Another noteworthy conversation that sprung week: Scott Rosenberg, Dave Winer, and Amy Gahran on why journalists should be wary of Facebook — because eventually, as Rosenberg said, "it’s not the public sphere, not in the way the Internet itself is. It’s just a company."
— The Wall Street Journal became the latest news org to launch a platform modeled after the WikiLeaks anonymous leaking concept, with SafeHouse. The Atlantic has plenty of details.
— Finally, two useful sets of tips: One from Poynter's Julie Moos about news blogging from filling in for Jim Romenesko for a week, and the other from TBD's Steve Buttry on possible revenue streams for newspapers.
Similar posts: Retin A Over The Counter. Synthroid No Rx. Zoloft Dosage. Retin A brand name. Flagyl photos. Diflucan brand name.
Trackbacks from: Armour Dosage. Armour Dosage. Armour Dosage. Buy Armour from mexico. Ordering Armour online. Armour no rx.